LGVN - Longeveron Inc.
IEX Last Trade
1.805
0.065 3.601%
Share volume: 0
Last Updated: Thu 26 Dec 2024 04:29:49 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
4.47%
PREVIOUS CLOSE
CHG
CHG%
$1.74
0.07
3.74%
Fundamental analysis
6%
Profitability
0%
Dept financing
11%
Liquidity
41%
Performance
2%
Performance
5 Days
6.67%
1 Month
-10.20%
3 Months
-9.74%
6 Months
-6.38%
1 Year
31.34%
2 Year
-46.18%
Key data
Stock price
$1.80
DAY RANGE
N/A - N/A
52 WEEK RANGE
$1.06 - $14.50
52 WEEK CHANGE
-$87.34
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/08/2024
Company detail
CEO: K. Chris Min
Region: US
Website: longeveron.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: longeveron.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Longeveron Inc. develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product. It is conducting Phase 1 and 2 clinical trials in various indications.
Recent news